Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vandetanib + ranitidine
- Development stage
- Phase 1
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
01
Overview
Combination of vandetanib, a small-molecule inhibitor of vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and RET tyrosine kinases indicated for unresectable or metastatic medullary thyroid cancer, and ranitidine, a histamine H2-receptor antagonist used for acid-related gastrointestinal disorders. Both drugs are co-administered in certain clinical scenarios. Available data show no clinically relevant pharmacokinetic or pharmacodynamic interaction between vandetanib and ranitidine, and no dose adjustment is required when co-administered[1][2][3][5][6].
- Other names
- N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine
02
Targets
PTK6 (Protein-tyrosine kinase 6)EGFR (Epidermal growth factor receptor)EPHB2 (Ephrin type-B receptor 2)HRH2 (Histamine H2 Receptor)RET (Rearranged during transfection receptor tyrosine kinase)SFK (SRC family kinases)TEK (Tie2)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on vandetanib + ranitidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vandetanib + ranitidine.